🔎 Trials Near Me

Home › Major Depressive Disorder › NCT04061148

Near Infrared Spectroscopy (NIRS) for Assessment of Depression

RecruitingHealthy volunteers welcome

Clinical Testing of Near Infrared Spectroscopy (NIRS) for Quantitative Assessment of Depression

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* All subjects who sign informed consent.
* Controls: Volunteers over 18 years of age who are not depressed.
* Patients over 18 years of age with a diagnosis of Major Depressive Disorder, receiving clinical therapy at SFVAMC.

Exclusion Criteria:

* Subjects who cannot sign informed consent.
* Exclusion criteria for control subjects: 1.Depression 2.Anxiety, psychotic, substance abuse, mood and personality disorders 3.Major neurocognitive disorders such as Alzheimer's disease and other dementias 4.Neurologic disorders with anatomic lesions including traumatic brain injury, stroke, tumor and arteriovenous malformation
* Exclusion criteria for depressed patients: 1.Psychotic disorders like schizophrenia 2.Major neurocognitive disorders such as Alzheimer's disease and other dementias 3.Neurologic disorders with anatomic lesions including traumatic brain injury, stroke, tumor and arteriovenous malformation 4.Not receiving clinical therapy for depression at SFVAMC'

About the study

Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and reliably distinguishes the symptoms and severity of depression, with the help of repeated measure (up to five visits per subject) comparison of patients being treated for Major Depressive Disorder with control, non-depressed subjects.

What is being tested

Sponsor: University of California, San Francisco · Participants: 90 · Started: Jan 4, 2019

Contact the study team

Official record on ClinicalTrials.gov — NCT04061148

Locations in the U.S.

CaliforniaSan Francisco Veterans Affairs Medical Center, San Francisco

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.